## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($263.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Levi & Korsinsky Reminds Shareholders of an Investigation into The Cigna Group (CI) Regarding Potential Securities Fraud Allegations**
- Source: ACCESS Newswire | 20251222T140602 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) concerning potential federal securities law violations. This follows a significant drop in CI's stock price by 17% on October 30, 2025, after the company reported an increased Healthcare MCR for Q3 2025, which reduced future profitability expectations. Shareholders are encouraged to seek additional information regarding these allegations.

**2. Levi & Korsinsky Reminds Shareholders of an Investigation into The Cigna Group (CI) Regarding Potential Securities Fraud Allegations**
- Source: KXAN Austin | 20251222T130815 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential securities fraud. This follows a significant drop in CI's stock price by 17% on October 30, 2025, after the company reported third-quarter earnings showing a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, impacting future profitability. The firm encourages affected investors to seek additional information regarding potential legal action.

**3. UnitedHealth Group Stock (UNH) After Hours: Trump Premium Comments, New Audit “Action Plans,” and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251220T020817 | Somewhat-Bearish | Relevance: 73%
- UnitedHealth Group (UNH) stock experienced volatility due to President Trump's call for insurers to cut premiums and the company's release of 23 operational "action plans" from an independent review. The market is also closely watching the expiration of ACA subsidy expansions and the company's upcoming Q1 2026 review results for HouseCalls-related medical records. Investors will be focused on policy developments from Washington and the implementation of UnitedHealth's action plans as key drivers for Monday's market open.

**4. Tenet Healthcare (THC): Valuation Check as Policy Debates and Cigna Dispute Draw Investor Focus**
- Source: Simply Wall Street | 20251220T060913 | Neutral | Relevance: 72%
- Tenet Healthcare (THC) is under investor scrutiny due to strong earnings and a potentially undervalued stock, despite policy debates regarding the Affordable Care Act and a Cigna contract dispute. While its current P/E ratio of 12.7x is significantly lower than industry averages, suggesting undervaluation, a discounted cash flow model indicates an even deeper value, with a fair value of around $370.12. However, these positive valuations are tempered by risks associated with potential changes to ACA subsidies and the outcome of the Cigna dispute.

**5. ITGR SHAREHOLDERS: Integer Holdings Corporation Class Action Deadline is Approaching, Investors Notified to Contact BFA Law by February 9**
- Source: marketscreener.com | 20251220T090901 | Neutral | Relevance: 64%
- (Newsfile Corp. - December 20, 2025) - Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation (NYSE: ITGR) and its senior executives for alleged securities fraud, following a significant stock drop. The lawsuit claims Integer overstated demand for its electrophysiology devices, leading to a stock decline of over 32% on October 23, 2025. Investors who held Integer stock are encouraged to contact BFA Law by February 9, 2026, to potentially lead the case.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 8.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.6B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.3 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.0% to 0.5% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.04), confirming momentum. RSI neutral at 53. OFD pattern: +F0L (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.53% (CS: 62) | Neutral |
| RSI_14 | 52.8 | Neutral |
| MACD Histogram | 1.04 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 0.914x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $275.55
- **Stop Loss:** $263.31 (4.4% risk)
- **Target:** $287.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 98
- **Position Value:** $27,003.90
- **Portfolio %:** 27.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*